Activity of raloxifene in immature and ovariectomized rat uterotrophic assays

Regulatory Toxicology and Pharmacology

Volumn 25, Issue 3, 1997, Pages 226-231

  Ashby, J ^a   Odum, J ^a   Foster, J R ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; RALOXIFENE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; FEMALE; HISTOLOGY; IMMATURITY; MITOSIS RATE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; UTERUS GROWTH; UTERUS WEIGHT;

ANIMALIA;

EID: 0031171316     PISSN: 02732300     EISSN: None     Source Type: Journal    
DOI: 10.1006/rtph.1997.1108     Document Type: Article

References (15)

1. Black, L. J., Sato, M., Rowley, E. R., Magee, D. E., Bekele, A., Williams, D. C., Cullinan, G. J., Bendele, R., Kauffman, F. G., Bensch, W. R., Frolik, C. A., Termine, J. D., and Bryant, H. U. (1994). Raloxifene prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin. Invest. 93, 63-69.
2. Colborn, T., vom Saal, F. S., and Soto, A. M. (1993). Developmental effect of endocrine disrupting chemicals in wildlife and humans. Environ. Health Perspect. 101, 378-385.
3. Colborn, T., and Clement, C. (Eds.) (1992). Chemically-Induced Alterations in Sexual and Functional Development. Princeton Scientific Publishing.
4. Evans, G. L., Bryant, H. U., Magee, D. E., and Turner, R. T. (1996). Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia. Endocrinology 137, 4139-4144.
5. Feldman, D. (1997). Editorial: Estrogens from plastic - Are we being exposed? Endocrinology 138, 1777-1779.
6. Jones, C. D., Javnicar, M. G., Pike, A. J., Peters, M. K., Black, L. J., Thompson, A. R., Falcone, J. F., and Clemens, J. A. (1984). Antiestrogens. 2. Structure-activity studies in a series of 6-aroyl-2-aryl benzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b] thien-3-yl][4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J. Med. Chem. 27, 1057-1066.
7. Kavlock, R. J., Daston, G. P., DeRosa, C., Fenner-Crisp, P., Gray, L. E., Kaattari, S., Lucier, G., Luster, M., Mac, M. J., Maczka, C., Miller, R., Moore, J., Rolland, R., Scott, G., Sheehan, D. M., Sinks, T., and Tilson, H. A. (1996). Research needs for the risk assessment of health and environmental effects of endocrine disrupters: A report of the U.S. EPA-sponsored workshop. Environ. Health Perspect. 104(Suppl. 4), 715-740.
8. O'Connor, J. C., Cook, J. C., Craven, S. C., Van Pelt, C. S., and Obourn, J. D. (1996). An in vivo battery for identifying endocrine modulators that are estrogenic or dopamine regulators. Fundam. Appl. Toxicol. 33, 182-195.
9. Odum, J., Lefevre, P. A., Tittensor, S., Paton, D., Harris, C. A., Beresford, N. A., Sumpter, J. P., and Ashby, J. (1997). The rodent uterotrophic assay: Critical protocol features, studies with nonylphenols, and comparison with a yeast estrogenicity assay. Regul. Toxicol Pharmacol., in press.
10. Penissi, E. (1996). Drug's link to genes reveals estrogen's many sides. Science 273, 1171.
11. Reel, J. R., Lamb, J. C., and Neal, B. H. (1996). Survey and assessment of mammalian estrogen biological assays for hazard characterization. Fundam. Appl. Toxicol. 34, 288-305.
12. Shelby, M. D., Newbold, R. R., Tully, D. B., Chae, K., and Davis, V. L. (1996). Assessing environmental chemicals for estrogenicity using a combination of in vitro and in vivo assays. Environ. Health Perspect. 104, 1296-1300.
13. Wakeling, A. E., and Valcaccia, B. (1983). Antiestrogenic and antitumour activities of a series of non-steroidal antiestrogens. J. Endoer. 99, 445-464.
14. Yang, N. N. (1997). Correction: Raloxifene response needs more than an element. Science 275, 1249.
15. Yang, N. N., Venugopalan, M., Hardikar, S., and Glasebrook, A. (1996). Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 273, 1222-1225.